An early stage clinical trial of h11B6 in prostate cancer
Latest Information Update: 27 Jan 2020
At a glance
- Drugs H 11B6 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
Most Recent Events
- 27 Jan 2020 New trial record
- 21 Jan 2020 According to an Diaprost media release, the company entered into an exclusive Research and Option Agreement with a Top 10 Pharmaceutical company strategic partner in October 2017. Diaprost now announces that its strategic partner has exercised its option to acquire rights to its h11B6 antibody. An upfront payment and research funding has already been paid and an early-stage clinical trial has been initiated.